The briefing
A new pancreatic cancer drug carries a monthly price comparable to a home down payment, drawing criticism from doctors who call the cost unjustified. The U.S. manufacturer says the pricing supports innovation, intensifying debate over affordability and value in oncology care.
Original headline
A new cancer drug costs as much as a home down payment each month. Doctors say that’s greed, not health care